←Back to Expert Scholars
Translational Medicine / 转化医学Emerging Lung Targets
Alexander Drilon
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Chief, Early Drug Development Service
78
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Alexander Drilon leads MSKCC's early drug development efforts in thoracic oncology. He pioneered clinical development of selpercatinib, capmatinib and other selective inhibitors against rare lung oncogenes. His translational work established multiple new standards of care for biomarker-selected NSCLC.
Share:
🧪Research Fields 研究领域
MET exon 14
RET fusions
NTRK fusions
Early-phase trials
Oncogene drivers
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Alexander Drilon 的研究动态
Follow Alexander Drilon's research updates
留下邮箱，当我们发布与 Alexander Drilon（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment